Business Context and Reporting Period
Company: Compass Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 2, 2022
Reporting Period: Event-based report regarding a private placement and board appointment.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, or cash flow data. Key capital metrics disclosed include:
- Private Placement Size: 25,000,000 shares of Common Stock.
- Purchase Price: $3.21 per share.
- Gross Proceeds: Approximately $80 million (before fees and expenses).
- Use of Proceeds: Funding clinical development of CTX-009, CTX-471, and CTX-8371; preclinical development; research; working capital; and general corporate purposes.
- Cash Runway: Expected to extend into 2026.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement for a private placement of equity securities. This transaction represents a significant capital raise intended to fund the company's pipeline and operations. Additionally, the company entered into a Registration Rights Agreement requiring the filing of a registration statement within 30 days of closing.
Guidance, Outlook, and Corporate Governance
Outlook: Management anticipates the net proceeds will extend the company's cash runway into 2026, supporting the advancement of its clinical and preclinical programs.
Board Appointment: James P. Boylan, CEO of Enavate Sciences, was appointed as a Class II director effective upon the closing of the private placement. His term expires at the 2025 annual meeting. The Board determined Mr. Boylan is independent under Nasdaq listing rules.
Risks and Contingencies: The closing of the private placement is subject to customary closing conditions. The shares issued are unregistered and may not be resold absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the actual closing date of the private placement (anticipated no later than November 8, 2022).
- Confirm the final net proceeds after deducting placement agent fees and offering expenses.
- Review the full text of the Securities Purchase Agreement and Registration Rights Agreement in the subsequent Form 10-Q.
- Monitor the filing of the registration statement for resale of shares, required within 30 days of closing.
- Check for any updates on the compensation arrangement for the newly appointed director, James P. Boylan.